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Background: Colorectal cancer is the third most commonly diagnosed cancer worldwide. Few studies have
addressed the causes and risks of treatment refusal in a universal health insurance setting.
Methods: We examined the characteristics and survival associated with treatment refusal in patients with newly
diagnosed colorectal cancer in Taiwan during 2004–2008. Treatment refusal was defined as not undergoing any
cancer treatment within 4 months of confirmed cancer diagnosis. Patient data were extracted from four national
databases. Factors associated with treatment refusal were identified through logistic regression using the
generalized estimating equation method, and survival analysis was performed using the Cox proportional
hazards model.
Results: Of the 41,340 new colorectal cancer cases diagnosed, 3,612 patients (8.74%) refused treatment. Treatment
refusal rate was higher in patients with less urbanized areas of residence, lower incomes, preexisting catastrophic
illnesses, cancer stages of 0 and IV, and diagnoses at regional and district hospitals. Logistic regression analysis
revealed that patients aged >75 years were the most likely to refuse treatment (OR, 1.87); patients with catastrophic
illnesses (OR, 1.66) and stage IV cancer (OR, 1.43) had significantly higher refusal rates. The treatment refusers had
2.66 times the risk of death of those who received treatment. Factors associated with an increased risk of death in
refusers included age ≥75 years, insured monthly salary ≥22,801 NTD, low-income household or aboriginal status,
and advanced cancer stage (especially stage IV; HR, 11.33).
Conclusion: Our results show a lower 5-year survival for colorectal patients who refused treatment than for those
who underwent treatment within 4 months. An age of 75 years or older, low-income household status, advanced
stages of cancer, especially stage IV, were associated with higher risks of death for those who refused treatment.
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According to World Health Organization, cancer caused
7.6 million deaths (around 13% of all deaths) worldwide
in 2008, and cancer-related deaths are expected to con-
tinue to rise. In 2008, approximately 70% of cancer deaths
occurred in low-income and middle-income countries.* Correspondence: wtsai@mail.cmu.edu.tw
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unless otherwise stated.Cancer could affect over 13 million people worldwide by
the year 2030 [1]. In the United States, colorectal cancer is
the third most common cancer in both men and women
and is also the third leading cause of cancer-related deaths
[2], with an age-adjusted annual incidence per 100,000 of
51.7 in men and 39.1 in women in 2006–2010, down from
57.2 and 42.5, respectively, in 2003–2007 [3]. In Taiwan,
colorectal cancer is on the rise, and the age-adjusted an-
nual incidence per 100,000 increased from 37.99 in men
and 29.29 in women in 2003 to 54.39 in men and 36.84 inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Liu et al. BMC Cancer 2014, 14:446 Page 2 of 10
http://www.biomedcentral.com/1471-2407/14/446women in 2010 [4], rivaling the rates observed in the
United States. According to Taiwan Cancer Registry’s vital
statistics for new cancer cases in 2006–2010 (followed
up until 2011), the five-year survival rates for colorectal
cancer in men and women were 60.1% and 60.6%, re-
spectively [5].
Most, but not all, patients diagnosed with colorectal
cancer receive treatment. In the United States, propor-
tion of colon cancer patients who received no treatment
in 2012 was 1% for stages I and II, <1% for stage III, and
12% for stage IV; among rectal cancer patients, the pro-
portions were 2% for stages I and II and 4% for stages III
and IV [6]. Huchcroft and Snodgrass found that 7.5 out
of 1000 cancer patients refused treatment [7]. A small
study in older cancer patients observed a rate of 15.2%
for partial or complete treatment refusal [8]. Various
studies have found that 15.2% of patients refused recom-
mended chemotherapy [9]; 8% of cancer patients did not
undergo conventional cancer treatment [10]; 32% failed
to complete cancer treatment [11]; and among breast
cancer patients, 6% of those less than 65 years old and
22.2% of those 65 years or older did not receive standard
treatment [12]. As most of the above studies were small-
scale analyses, we were interested in conducting a nation-
wide study to examine treatment refusal among colorectal
cancer patients in Taiwan.
A limited number of studies have examined the risks
and possible causes of under treatment of cancer. One
study conducted in Israel found that cancer patients
who dropped out of chemotherapy, while not experien-
cing significantly different quality of life than those who
refused the therapy, had a lower quality of life than pa-
tients who completed chemotherapy [13]. A systematic
literature review concluded that chemotherapy has similar
effectiveness and safety for elderly (aged ≥65 years) and
nonelderly colon cancer patients, suggesting that elderly
patients should be prescribed chemotherapy [14]. One
study found that 27% of stage III colon cancer patients in
Alberta, Canada, did not receive chemotherapy, and in
18% of these cases, the reason was the physicians’ not
recommending the therapy, frequently because of the pre-
sence of one or more comorbidities [15]. Some terminal
cancer patients’ refusal or avoidance of treatment was
found to be related to a desire for death stemming from
depression and feelings of hopelessness [16]. However,
medical care professionals’ active surveillance and planning
of future treatments were shown to positively influence
patients’ desire to follow through with treatment [17].
Taiwan’s National Health Insurance program was
launched in 1995 to ensure health insurance coverage
for all people in Taiwan. Currently with a 99.9% coverage,
this program has succeeded in making quality health care
universal and affordable for patients [18]. The insur-
ance premiums of low-income households are paid bythe government, and copayments for the average person
are also very low. Furthermore, copayments are waived for
catastrophic illnesses and injuries (including cancer) in
order to lower the barriers to health care access. Never-
theless, a small proportion of cancer patients in Taiwan
choose not to undergo treatment for their cancer, and few
data are available on the causes of this treatment refusal.
In this study, we focused on colorectal cancer patients in
Taiwan who refused treatment, and examined the patients’
characteristics, survival risks, and related factors.
Methods
Study population and data collection
During 2004–2008, a total of 52,324 new cases of colo-
rectal cancer were diagnosed in Taiwan [19]. Of these, we
included 41,340 cases classified as International Classifica-
tion of Diseases for Oncology (ICD-O) codes C180–C218,
which amounted to 79% of all colorectal cancer cases
nationwide during that period. Treatment refusal was
defined as not undergoing conventional cancer treatment
(including surgery, radiation therapy, chemotherapy, radi-
ation therapy with concurrent chemotherapy, and targeted
therapy) more than 4 months of confirmed cancer diagno-
sis. This 4-month period was chosen because it is also the
time frame of cancer treatment used by Taiwan’s National
Cancer Registry. As reported by Tsai in 2013, the cumu-
lative treatment rate for colorectal cancer was 87.71% at
1 month of diagnosis, 94.01% at 4 months, 94.35 at
5 months, and 95.48% at 12 months [20], indicating very
little increase in the cumulative treatment rate from the
fifth month, thus supporting our assumption of treatment
refusal for newly diagnosed cancer patients who remained
untreated after 4 months. Cancer patients receiving only
palliative care were excluded from our analysis.
Cancer registration in Taiwan began in 1979. The
patient data analyzed in this study were retrieved from
four complete databases as follows. (i) The 2004–2008
Taiwan Cancer Registry Database (TCRD) of Taiwan’s
Health Promotion Administration, Ministry of Health
and Welfare provided data on sex, age at diagnosis, cancer
stage, and treatment vs. no treatment. (ii) The National
Health Insurance Research Database (NHIRD) of Taiwan’s
National Health Insurance Administration provided data
on sex, age at diagnosis, urbanization level of residence
location, insured monthly salary, low-income household
status, other catastrophic illnesses or injuries, comorbidity
for calculating Charlson Comorbidity Index (CCI), level of
diagnosing or treatment hospital, and ownership type of
diagnosing or treatment hospital. (iii) Taiwan’s cause-of-
death database profile: survival or not at the end of 2010
provided data on post-diagnosis survival in deceased
patients. (iv) The Aboriginal Committee’s aboriginal
status records of Taiwan’s Ministry of the Interior pro-
vided data on aboriginal status. Urbanization levels of
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classification system, which includes seven levels (from
the most to the least urbanized): level 1, highly urbanized
cities; level 2, moderately urbanized cities; level 3, develop-
ing cities; level 4, average towns; level 5, aging towns; level
6, agricultural towns; and level 7, remote villages [21].
Statistical analysis
To analyze factors associated treatment refusal, we chose
to test a set of patient and hospital characteristics, includ-
ing the following variables: basic personal characteristics
(sex, age at diagnosis, urbanization level of residence loca-
tion, and aboriginal status), socioeconomic status (insured
monthly salary and low-income household status), health
status (preexistence of catastrophic illnesses or injuries
other than cancer, and cancer stage), and characteristics of
the diagnosing hospital (hospital level and hospital owner-
ship type). First, we described the 2004–2008 patient set
in terms of the proportion that received treatment and the
proportion that refused treatment, and stratified the
two groups by patient and hospital characteristics. Next,
Student’s t test and the chi-square test were applied to
determine whether the treated and untreated patients
differed in patient or hospital characteristics. In addition,
in order to adjust for the cluster effect, logistic regression
was performed using the generalized estimating equation
(GEE) method to identify those factors that correlated
with treatment refusal.
To analyze effects on patient survival, we first com-
puted the 1- through 5-year survival rates for the treated
and untreated patients, and then examined by ANOVA
whether post-diagnosis survival differed among deceased
patients with different stages of cancer. The starting point
of the survival analysis was a confirmed cancer diagnosis,
and the endpoint was patient death or the last follow-up
on survival status at the end of 2010, whichever was
sooner. We also examined by the chi-square test whether
survival differed among patients differing in basic personal
characteristics, socioeconomic status, health status, seve-
rity of cancer, and hospital characteristics. Finally, sur-
vival analysis using the Cox proportional hazards model
was performed, while controlling for the contributions
of individual patient and hospital factors, in order to
analyze the effect of treatment refusal on survival and
the factors that influenced survival in treatment refusers.
Statistical analysis was performed with SAS software,
version 9.3.
The Statistics Center of Department of Health, Taiwan,
helped us combine all data sets with personal identifi-
cation number and then provided us the data sets in-
cluding the necessary information for this study. All
personal identification information has been deleted,
and personal privacy was under protection from using
these data. This study has been approved by the researchethics committee in China Medical University and Hospital
(IRB No. CMUH102-REC3-076).
Results
During 2004–2008, a total of 42,340 new cases of
colorectal cancer were diagnosed, in 3,612 of which
the patient refused treatment. The various patient and
hospital characteristic for these cases are described in
Table 1. In terms of patient baseline characteristics, the pro-
portion of treatment-refusing (untreated) patients tended
to increase with increasing age at diagnosis, whereas the
proportion of treated patients was similar in all age groups,
but was the lowest in the ≥75 years group. The treatment-
refusing group was on average 4.6 years older than the
treated group (69.52 ± 14.47 vs. 64.92 ± 13.58 years); pa-
tients residing in more urbanized areas had lower rates of
treatment refusal, as did patients with higher monthly in-
come levels (refusal rate dropping from 9.57% for insured
dependents to 5.70% for the ≥22,801 NTD group); higher
treatment-refusal rates were observed in patients with pre-
existing catastrophic illnesses or injuries (16.12% vs. 8.45%
without such preexisting conditions) and in patients with
stage 0 and stage IV cancer (8.15% and 12.98%). Among
deceased patients who had refused treatment, those with
stage III cancer survived the longest post-diagnosis
(1.62 ± 1.31 years), while those with stage IV cancer sur-
vived for the shortest time (0.53 ± 0.77 years). Among de-
ceased patients who had received treatment, post-diagnosis
survival was the longest for stage I cancer (2.32 ± 1.64 years)
and the shortest for stage IV cancer (1.23 ± 1.01 years).
Treated patients of every cancer stage lived longer post-
diagnosis than untreated patients of the same cancer stage.
In terms of characteristics of the diagnosing hospital,
patients diagnosed at medical centers—or the highest
hospital level—had the lowest treatment refusal rate
(6.22%). Sex, aboriginal status, and ownership type of
the diagnosing hospital did not have statistically sig-
nificant correlations with patients’ refusing or under-
going treatment (P > 0.05).
To analyze patient and hospital factors related to treat-
ment refusal, we performed logistic regression analysis
using a generalized estimating equation (GEE) model
(Table 2). We found that treatment refusal rate increased
significantly with increasing patient age at diagnosis, with
the highest rate being observed in patients aged ≥75 years
(adjusted odds ratio [adj. OR], 1.87; 95% confidence
interval [95% CI], 1.55–2.26). Treatment refusal rate
also decreased significantly with increasing insured
monthly salary (adj. OR, 0.79; 95% CI, 0.69–0.89) and
increased significantly with preexisting catastrophic ill-
nesses or injuries (adj. OR, 1.66; 95% CI, 1.37–2.02). In
terms of cancer stage, treatment refusal rate was signifi-
cantly higher in stage IV patients (adj. OR, 1.32; 95% CI,
1.03–1.69) and significantly lower in stage I through III
Table 1 Patient and hospital characteristics of colorectal cancer patients, by treatment choice (untreated vs. treated)
Variable No. of patients Untreated Treated P value
N % N %
Total colon cancer patients 41,340 3,612 8.74 37,728 91.26
Sex 0.893
Female 17,862 1,565 8.76 16,297 91.24
Male 23,478 2,047 8.72 21,431 91.28
Age at diagnosis, years <0.001*
≤44 3,113 209 6.71 2,904 93.29
45–54 6,298 426 6.76 5,872 93.24
55–64 8,584 539 6.28 8,045 93.72
65–74 11,219 843 7.51 10,376 92.49
≥75 11,991 1,572 13.11 10,419 86.89
Age at diagnosis, years (M ± SD) 41,340 69.52 14.47 64.92 13.58 <0.001*
Urbanization level of residence location 0.012*
Level 1 (highest) 12,201 1,015 8.32 11,186 91.68
Level 2 11,812 1,031 8.73 10,781 91.27
Level 3 6,211 529 8.52 5,682 91.48
Level 4 6,133 544 8.87 5,589 91.13
Level 5 1,230 115 9.35 1,115 90.65
Level 6 1,876 207 11.03 1,669 88.97
Level 7 (lowest) 1,738 148 8.52 1,590 91.48
Aboriginal status 0.501
No 41,115 3,589 8.73 37,526 91.27
Yes 225 23 10.22 202 89.78
Insured monthly salary, NTD <0.001
≤17,280 8,551 850 9.94 7,701 90.06
Insured dependent 12,728 1,218 9.57 11,510 90.43
17,281–22,800 13,153 1,134 8.62 12,019 91.38
≥22,801 6,769 386 5.70 6,383 94.30
Low-income household status 0.008*
No 30,766 2,508 8.15 28,258 91.85
Yes 363 44 12.12 319 87.88
Other catastrophic illnesses or injuries <0.001*
No 39,814 3,366 8.45 36,448 91.55
Yes 1,526 246 16.12 1,280 83.88
Cancer stage <0.001*
Stage 0 1,559 127 8.15 1,432 91.85
Stage I 6,478 195 3.01 6,283 96.99
Stage II 9,078 204 2.25 8,874 97.75
Stage III 12,254 313 2.55 11,941 97.45
Stage IV 9,131 1,185 12.98 7,946 87.02
Other/Unknown 2,840 1,588 55.92 1,252 44.08
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Table 1 Patient and hospital characteristics of colorectal cancer patients, by treatment choice (untreated vs. treated)
(Continued)
Post-diagnosis survival in deceased patients, years (M ± SD) <0.001*
Stage 0 1,559 1.57 1.81 1.97 1.47
Stage I 6,478 1.61 1.46 2.32 1.64
Stage II 9,078 1.19 1.28 2.08 1.51
Stage III 12,254 1.62 1.31 2.00 1.39
Stage IV 9,131 0.53 0.77 1.23 1.01
Level of diagnosing hospital <0.001*
Medical center 56,511 1,649 6.22 24,862 93.78
Regional hospital 12,024 1,431 11.90 10,593 88.10
District hospital 1,464 280 19.13 1,184 80.87
Ownership type of diagnosing hospital
Public 12,169 1,057 8.69 11,112 91.31 0.416
Private 28,325 2,389 8.43 25,936 91.57
*P < 0.05.
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patients as the reference group. With regard to level
of the diagnosing hospital, cancer diagnoses made at
regional hospitals (adj. OR, 1.54; 95% CI, 1.09–2.17)
and district hospitals (adj. OR, 1.82; 95% CI, 1.27–2.61)
were significantly more likely to result in treatment refusal
than those made at medical centers, the reference group.
Patients with higher CCI scores were more likely to refuse
treatment. Sex, aboriginal status, low-income household
status, and hospital ownership type were not significantly
correlated with treatment refusal (P > 0.05).
Next, we analyzed whether treatment refusal had an ef-
fect on the survival of colorectal cancer patients (Table 3).
After other variables’ effects were adjusted for, we found
that patients who refused treatment had 2.66 times the
risk of death as those who underwent treatment (95% CI,
2.49–2.84). The risk of death was lower in male patients
than in female patients (adj. HR, 0.92; 95% CI, 0.88–0.96)
and was significantly higher in patients residing in the
least urbanized (level 7) areas (adj. HR, 1.17; 95% CI,
1.07–1.28). The risk of death also increased significantly
with increasingly advanced stage of cancer diagnosed, with
stage IV patients being the most likely to die (adj. HR,
19.38; 95% CI, 15.96–23.54). When we analyzed the
1- through 5-year survival rates of treated and untreated
patients (Figure 1), we found that these rates were signifi-
cantly lower in treatment refusers than in treated patients.
Finally, we analyzed characteristics of treatment-refusing
patients that might have affected these patients’ survival,
and the results are presented in Table 4. Among treatment
refusers, those aged ≥75 years had a significantly higher
risk of death than those in other age groups (adj. HR, 1.59;
95% CI, 1.20–2.09); those who were aboriginals had a
significantly lower risk of death (adj. HR, 0.33; 95% CI,
0.13–0.81), as did those who had the highest (≥22,801NTD) insured monthly salary (adj. HR, 0.74; 95% CI,
0.60–0.92); belonging to a low-income household signifi-
cantly raised the risk of death (adj. HR, 1.71; 95% CI,
1.07–2.72). In addition, higher CCI scores were associated
with significantly increased risks of death, especially
in patients with a CCI ≥7 (adj. HR, 15.96; 95% CI, 14.43–
17.65). The risk of death in treatment refusers also in-
creased significantly with increasingly advanced stage of
cancer, with stage IV patients having the highest risk (adj.
HR, 11.33; 95% CI, 7.55–17.00). Sex, urbanization level of
residence location, and preexisting catastrophic illnesses
or injuries were not significantly correlated with survival
in treatment refusers (P > 0.05).
Discussion
In this study, we examined patient- and hospital-related
factors and survival risks associated with treatment refusal
in newly diagnosed colorectal cancer patients in Taiwan
during 2004–2008.
One study showed that cancer patients who were single,
divorced, or widowed or who were female were more
likely to refuse cancer treatment; the authors speculated
that male cancer patients were more likely to undergo
treatment because men are typically the providers of fi-
nancial support for their families [22]. In contrast, another
study that examined early-stage (stage I and stage II) lung
cancer patients reported a higher proportion of men than
women (66.7% vs. 33.3%) among the treatment refusers
[23]. Our present study revealed no significant difference
in gender distribution between treated and treatment-
refusing colorectal cancer patients. The discrepancies be-
tween our finding and those of Kleffens et al. and Chadha
et al. could have arisen from differences in the health
insurance systems in the patients’ countries. Due to the
national health insurance program that provides universal
Table 2 GEE logistic regression analysis of correlations
between patient and hospital characteristics and
treatment refusal in colorectal cancer patients
Variable GEE analysisa
Adj. OR 95% CI P value
Sex
Female (reference group) - - - -
Male 1.06 0.98 1.14 0.172
Age at diagnosis, years
≤44 (reference group) - - - -
45–54 1.13 0.97 1.31 0.112
55–64 1.14 1.01 1.29 0.028*
65–74 1.24 1.06 1.45 0.009*
≥75 1.87 1.55 2.26 <0.001*
Urbanization level of
residence location
Level 1 (highest; reference group) - - - -
Level 2 0.97 0.86 1.08 0.555
Level 3 0.90 0.78 1.04 0.144
Level 4 0.89 0.76 1.05 0.172
Level 5 1.01 0.82 1.24 0.961
Level 6 1.01 0.82 1.23 0.961
Level 7 (lowest) 0.96 0.76 1.22 0.761
Aboriginal status
No (reference group) - - - -
Yes 0.80 0.51 1.24 0.317
Insured monthly salary, NTD
≤17,280 (reference group) - - - -
Insured dependent 0.78 0.65 0.94 0.007*
17,281–22,800 0.90 0.80 1.00 0.048*
≥22,801 0.79 0.69 0.89 <0.001*
Low-income household status
No (reference group) - - - -
Yes 1.33 0.98 1.80 0.064
Other catastrophic illnesses or injuries
No (reference group) - - - -
Yes 1.66 1.37 2.02 <0.001*
Cancer stage
Stage 0 (reference group) - - - -
Stage I 0.38 0.29 0.48 <0.001*
Stage II 0.29 0.22 0.39 <0.001*
Stage III 0.35 0.27 0.47 <0.001*
Stage IV 1.32 1.03 1.69 0.029*
Charlson Comorbidity Index (CCI)
≤3 (reference group) - - - -
4–6 1.29 1.07 1.56 0.009*
≥7 1.28 1.05 1.56 0.013*
Table 2 GEE logistic regression analysis of correlations
between patient and hospital characteristics and
treatment refusal in colorectal cancer patients (Continued)
Level of diagnosing hospital
Medical center (reference group) - - - -
Regional hospital 1.54 1.09 2.17 0.013*
District hospital 1.82 1.27 2.61 0.001*
Ownership type of
diagnosing hospital
Public (reference group) - - - -
Private 0.86 0.63 1.17 0.330
aevent: treatment refusal *P < 0.05.
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Taiwanese, thus minimizing the effect of economic factors
on patients’ willingness to seek medical treatment.
The rate of treatment refusal has been shown to in-
crease with patient age [23-25]. We found the mean age
of colorectal cancer patients who refused treatment to
be 69.52 years, or 4.6 more years than that of patients
who underwent treatment; logistic regression analysis
using the GEE method showed that the likelihood of treat-
ment refusal increased significantly with increasing age
(adj. OR for the ≥75 years age group, 1.87; 95% CI,
1.55–2.26). These findings are consistent with those
of the three previous studies [23-25].
Huchcroft and Snodgrass’s study on treatment-refusing
cancer patients in Canada during 1975–1988 showed that
patients living in remote areas refused treatment at a
higher rate than those living in urban areas because of
lower access to medical care and lower availability of
advanced medical technologies [7]. This finding differs
from our finding of a lack of a statistically significant rela-
tionship between treatment refusal and urbanization level
of residence location. We speculate that, owing to the
National Health Insurance program, financial and access
barriers to medical care are lower in Taiwan than in many
Western countries, thus making access to care less of a
factor in the treatment status of the patients in our study
sample. With respect to socioeconomic characteristics,
our study showed that the rate of treatment refusal de-
creased with increasing level of patient insured monthly
salary, and the risk of death was significantly lower in the
highest insured monthly salary group (≥22801 NTD). This
result is in agreement with that of Yim et al.’s 2010 study,
and indicates that the cost of medical treatment is one of
the barriers to cancer patients’ compliance with prescribed
treatments [26].
Previous studies have shown that multiple cancers,
advanced-stage cancer, and worsening of disease are all
factors that contribute to patients’ refusal of or dropout
from treatment [7,25]. In our study, an advanced cancer
Table 3 Effect of treatment refusal on survival in
colorectal cancer patients
Variable Adj. HRa 95% CI P value
Treatment
Yes (reference group) - - - -
No 2.66 2.49 2.84 <0.001*
Sex
Female (reference group) - - - -
Male 0.92 0.88 0.96 <0.001*
Age at diagnosis, years
≤44( (reference group) - - - -
45–54 0.86 0.80 0.93 <0.001*
55–64 0.89 0.82 0.96 0.002*
65–74 1.04 0.96 1.12 0.366
≥75 1.75 1.63 1.88 <0.001*
Urbanization level of
residence location
Level 1 (highest; reference group) - - - -
Level 2 0.97 0.92 1.02 0.233
Level 3 1.06 1.00 1.13 0.052
Level 4 1.05 0.99 1.12 0.112
Level 5 1.05 0.95 1.17 0.333
Level 6 1.05 0.96 1.14 0.306
Level 7 (lowest) 1.17 1.07 1.28 0.001*
Aboriginal status
No (reference group) - - - -
Yes 0.89 0.71 1.12 0.328
Insured monthly salary, NTD
≤17,280 (reference group) - - - -
Insured dependent 0.97 0.90 1.05 0.455
17,281–22,800 1.00 0.95 1.05 0.908
≥22,801 0.80 0.75 0.85 <0.001*
Low-income household status
No (reference group) - - - -
Yes 1.53 1.32 1.79 <0.001*
Other catastrophic illnesses
or injuries
No (reference group) - - - -
Yes 1.83 1.68 2.00 <0.001*
Cancer stage
Stage 0 (reference group) - - - -
Stage I 1.59 1.30 1.95 <0.001*
Stage II 2.63 2.16 3.21 <0.001*
Stage III 3.84 3.16 4.68 <0.001*
Stage IV 19.38 15.96 23.54 <0.001*
aevent: death; the model has controlled for level of diagnosing hospital and
ownership type of diagnosing hospital.
*P < 0.05.
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were both significantly associated with higher rates of
treatment refusal. Besides the above characteristics,
other factors that influence patients’ decision to refuse
or drop out of treatment have been shown to include
health status, access to information on their condition,
attitude toward their condition, interactive relationships
with medical staff, and encouragement from medical
staff [27]. In their 2012 study on breast cancer patients
who opted for alternative therapies in place of conven-
tional treatment, Citrin et al. showed that the patients’
perception of unsympathetic physician attitudes (“uncar-
ing, insensitive, and unnecessarily harsh”), fear of side ef-
fects, and belief in the efficacy of alternative therapies
(such as consumption of raw fruits and vegetables and
nutritional supplements), were key factors in these pa-
tients’ refusal of conventional medical treatment [28]. In
the present study, our GEE-based regression modeling
also uncovered the level of the diagnosing hospital to be a
factor in treatment refusal, as colorectal cancer patients
diagnosed at regional and district hospitals were signi-
ficantly less likely to undergo treatment. Therefore,
we suggest that physicians at lower-level hospitals
refer their patients to medical centers for second opinions
and encourage the patients to actively seek treatment.
One noteworthy finding from our study is that stage
0 patients actually refused treatment at a higher rate
than stage 1 through III patients; this may mean that
health care staffs need to follow up on stage 0 pa-
tients more closely to ensure their receiving proper
treatment.
Kowalski and Carvalho’ 2000 study found that ap-
proximately 50% of untreated head and neck cancer pa-
tients die within 4 months of diagnosis [25]; Chadha
et al. determined the mean survival for untreated early-
stage lung cancer to be 11.9 months [23]. In the present
study, we found that untreated colorectal cancer patients
had lower 1- through 5- year survival rates and (for de-
ceased patients) shorter mean survival than their treated
counterparts. We also observed a higher risk of death in
colorectal cancer patients who were older or had higher
incomes, consistent with a previous study’s finding
that oral cancer patients who were younger and more
affluent had higher survival rates [29]. The 2010 study
by Yim et al. showed that survival prospects were
poorer for low-income cancer patients than for their
higher-income counterparts [26]. Kevin et al. also re-
ported in their 2011 study that low-income colon
cancer patients in San Francisco, United States, had
lower survival rates than their high-income counter-
parts, but income level had no such effect on cancer
patient survival in Toronto, Canada, where a publicly
funded health care system provides universal coverage
[30]. All the evidence above indicates that economic or
Figure 1 One- through five-year survival rates in treated and untreated colorectal cancer patients.
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patient survival.
Sant et al. analyzed data for 4,478 patients diagnosed
with breast cancer in 1990–1992 and found that stage
IV patients had 3.38 times the risk of death of stage I
patients [31]; Ma et al.’s study on lung cancer patients
found cancer stage to be the main factor affecting pa-
tient survival [32]. Consistent with these results, our
study found that advanced stages of colorectal cancer
were associated with higher risks of death, especially
stage IV (adj. HR, 19.38). Another study showed that stage
III colon cancer patients who received chemotherapy had
significantly higher overall survival than those who refused
it [33]. Similarly, a study from the Netherlands found that
stage III colon cancer patients treated with chemotherapy
during 1989–2006 had significantly lower risks of death
than those without chemotherapy [34]. Yet another study
showed that among cancer patients indicated for radiation
therapy, those who refused it significantly differed from
those who complied with it in terms of several variables
(age, race, marital status, and tumor location) and had a
median survival 75 months shorter than those who com-
plied [35]. In our present study, treatment-refusing cancer
patients had 2.66 times the risk of death of their treated
counterparts, with the risk being significantly higher for
stage IV patients (adj. HR, 11.33). This finding is consist-
ent with those reported in the literature, and suggests that
cancer patients should comply with treatments recom-
mended by their physicians for better clinical outcomes.
Indigenous Australians in Queensland have a lower
overall incidence of cancer, but a higher overall cancermortality, than the total population [36]. In a study
involving patients in the United States Military Health
System, Andaya et al. found that among colon cancer
patients younger than 50, non-Hispanic Blacks ex-
perienced significantly lower overall survival than non-
Hispanic Whites [37]. In our study with colorectal cancer
patients in Taiwan, although aboriginals had a somewhat
higher proportion of treatment refusers than non-aborigi-
nals (10.22% vs. 8.45%), aboriginal status was not corre-
lated with either treatment refusal or survival. It is
possible that our result differs from those of other studies
because Taiwan’s aboriginals experience few or no barriers
to health care access under the National Health Insurance
system.
Taiwan implements a universal health care system
and mandates the participation of its entire popula-
tion in order to remove barriers to people’s utilization
of medical services. Taiwan’s health administrations
also target remote areas with a mobile health policy
to promote the fairness and universality of health care.
Nevertheless, our study showed that in this environ-
ment of low-barrier, high-access medical care, some
cancer patients still refused treatment; more studies
are needed to further examine the reasons behind this
phenomenon.
This research was a database analysis focused on the
personal characteristics, socioeconomic status, and par-
tial state of health of treatment-refusing cancer patients.
Due to the use of secondary databases, which did not
collect information on such variables as patient health
behaviors, health belief and health awareness, we were
Table 4 Correlations between patient factors and survival
in treatment-refusing colorectal cancer patients
Variable Adj. HRa 95% CI P value
Sex
Female (reference group) - - - -
Male 1.03 0.91 1.17 0.650
Age at diagnosis, years
≤44 (reference group) - - - -
45–54 0.79 0.59 1.07 0.132
55–64 0.93 0.69 1.25 0.630
65–74 0.96 0.72 1.28 0.769
≥75 1.59 1.20 2.09 0.001*
Urbanization level of
residence location
Level 1 (highest; reference group) - - - -
Level 2 0.89 0.75 1.05 0.158
Level 3 1.06 0.87 1.30 0.578
Level 4 1.04 0.85 1.28 0.692
Level 5 0.89 0.63 1.26 0.510
Level 6 0.90 0.68 1.18 0.433
Level 7 (lowest) 1.27 0.95 1.69 0.115
Aboriginal status
No (reference group) - - - -
Yes 0.33 0.13 0.81 0.015*
Insured monthly salary, NTD
≤17,280 (reference group) - - - -
Insured dependent 0.98 0.75 1.28 0.889
17,281–22,800 0.92 0.79 1.08 0.330
≥22,801 0.74 0.60 0.92 0.007*
Low-income household status
No (reference group) - - - -
Yes 1.71 1.07 2.72 0.024*
Other catastrophic illnesses
or injuries
No (reference group) - - - -
Yes 1.26 0.98 1.60 0.070
Charlson Comorbidity Index (CCI)
≤3 (reference group) - - - -
4–6 7.31 6.54 8.16 <0.001*
≥7 15.96 14.43 17.65 <0.001*
Cancer stage
Stage 0 (reference group) - - - -
Stage I 1.48 0.92 2.38 0.110
Stage II 2.99 1.91 4.67 <0.001*
Stage III 3.58 2.35 5.46 <0.001*
Stage IV 11.33 7.55 17.00 <0.001*
aevent: death; the model has controlled for level of diagnosing hospital and
ownership type of diagnosing hospital.
*P < 0.05.
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fusing treatment with respect to these other variables.
Conclusion
Since its inception in 1995, Taiwan’s National Health
Insurance program has achieved 99.9% coverage and
succeeded in making quality health care universal and
affordable for patients. However, among the 41,340
new colorectal cancer cases diagnosed, 8.74% refused
treatment within 4 months. Our results show a lower
5-year survival and a 2.66-fold increased risk of death
for colorectal patients who refused treatment than for
those who underwent treatment within 4 months. There-
fore, we urge newly diagnosed cancer patients to ac-
tively seek treatment in order to enhance their chances of
survival.
We identified several important factors that corre-
lated with treatment refusal, including age at diagnosis,
urbanization level of residence location, insured monthly
salary, low-income household status, preexisting catastro-
phic illnesses or injuries, cancer stage, and level of
diagnosing hospital. We also found that an age of
75 years or older, low-income household status, ad-
vanced stages of cancer, especially stage IV, were associ-
ated with higher risks of death for those who refused
treatment.
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